Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal

First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M

By Richard Guy, Biopharma Analyst
August 19, 2022 10:24 PM UTC

Carlyle’s first late-stage biotech deal since its acquisition of Abingworth will be part of a $260 million funding package for Opthea to conduct Phase III testing of a selective VEGF inhibitor in ophthalmology.

The company said it was the largest-ever financing for an Australian biotech; there are none larger in BioCentury’s BCIQ database...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

Genentech Inc.

Novartis AG

Opthea Ltd.

Regeneron Pharmaceuticals Inc.

Roche

Samsung Bioepis Co. Ltd.